These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17668483)

  • 1. Capecitabine and irinotecan in advanced gastric cancer.
    Sharma SP
    Lancet Oncol; 2007 Jul; 8(7):577. PubMed ID: 17668483
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
    Zhao WY; Chen DY; Qi Q
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
    Liu Y; Kang MF; Luo MQ; Dong CM
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov; 30(11):2575-6. PubMed ID: 21097437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
    Oh SC; Sur HY; Sung HJ; Choi IK; Park SS; Seo JH; Jeen YT; Chun HJ; Shin SW; Mok YJ; Kim JS; Kim YH
    Br J Cancer; 2007 May; 96(10):1514-9. PubMed ID: 17473829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
    Baek JH; Kim JG; Jeon SB; Chae YS; Kim DH; Sohn SK; Lee KB; Choi YJ; Shin HJ; Chung JS; Cho GJ; Jung HY; Yu W
    Br J Cancer; 2006 May; 94(10):1407-11. PubMed ID: 16641916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
    Farhat FS; Kattan J; Chahine GY; Younes FC; Nasr FL; Mroue RM; Ghosn MG
    Med Oncol; 2010 Sep; 27(3):722-7. PubMed ID: 19644778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
    Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
    J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
    Luo HY; Wang ZQ; Wang FH; Qiu MZ; Teng KY; Ruan DY; He YJ; Li YH; Xu RH
    Am J Clin Oncol; 2011 Dec; 34(6):555-60. PubMed ID: 22101386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
    Punt CJ; Koopman M
    J Clin Oncol; 2008 Apr; 26(11):1907-8; author reply 1908-9. PubMed ID: 18398161
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient with angina secondary to capecitabine.
    Maciá-Escalante S; Guillén-Ponce C; Molina-Garrido MJ; Carrato-Mena A
    Clin Transl Oncol; 2005 Aug; 7(7):335. PubMed ID: 16185598
    [No Abstract]   [Full Text] [Related]  

  • 11. [The choice of treatment in advanced gastric cancer].
    Pozzo C; Mansueto G
    Tumori; 2007; 93(6):suppl 11-21. PubMed ID: 18338512
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
    Burge ME; Smith D; Topham C; Jackson DP; Anthoney DA; Halstead F; Seymour MT
    Br J Cancer; 2006 May; 94(9):1281-6. PubMed ID: 16622464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
    Hofheinz RD; Gnad-Vogt U; Wein A; Saussele S; Kreil S; Pilz L; Hehlmann R; Hochhaus A
    Anticancer Drugs; 2005 Jan; 16(1):39-45. PubMed ID: 15613902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
    Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
    Boers-Sonderen MJ; Desar IM; Koopman M; Punt CJ; van Herpen CM
    Acta Oncol; 2013 Nov; 52(8):1778. PubMed ID: 23777288
    [No Abstract]   [Full Text] [Related]  

  • 16. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
    Park SH; Bang SM; Cho EK; Baek JH; Oh JH; Im SA; Park YS; Shin DB; Lee JH
    Oncology; 2004; 66(5):353-7. PubMed ID: 15331921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
    Kim TW; Kang WK; Chang HM; Park JO; Ryoo BY; Ahn JS; Zang DY; Lee KH; Kang YK; Kim SR; Kim HK;
    Acta Oncol; 2005; 44(3):230-5. PubMed ID: 16076694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.
    Gennatas C; Michalaki V; Gennatas S; Papalambros E
    Anticancer Res; 2008; 28(3B):1923-6. PubMed ID: 18630482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.